Shahper KHAN

Dr. Shahper KHAN


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2026 in Frontiers in Artificial Intelligence
Verified
Journal Article
Open access
PDF file
SKShahper KHAN
Shahper KHAN
MKMohd Khan
Mohd Khan
LGLuca Guarnera
Luca Guarnera
SASyed Akhtar
Syed Akhtar
Precision healthcare is increasingly oriented toward the development of therapeutic strategies that are as individualized as the patients receiving them. Central to this paradigm shift is artificial intelligence (AI)-enabled multi-modal data integration, which consolidates heterogeneous data streams—including genomic, transcriptomic, proteomic, imaging, environmental, and electronic health record (EHR) data into a unified analytical framework. This integrative approach enhances early disease detection, facilitates the discovery of clinically actionable biomarkers, and accelerates rational drug development, with particularly significant implications for oncology, neurology, and cardiovascular medicine. Advanced machine learning (ML) and deep learning (DL) algorithms are capable of extracting complex, non-linear associations across data modalities, thereby improving diagnostic precision, enabling robust risk stratification, and informing patient-specific therapeutic interventions. Furthermore, AI-driven applications in digital health, such as wearable biosensors and real-time physiological monitoring, allow for continuous, dynamic refinement of treatment plans. This review examines the transformative potential of multi-modal AI in precision medicine, with emphasis on its role in multi-omics data integration, predictive modeling, and clinical decision support. In parallel, it critically evaluates prevailing challenges, including data interoperability, algorithmic bias, and ethical considerations surrounding patient privacy. The synergistic convergence of AI and multi-modal data represents not merely a technological innovation but a fundamental redefinition of individualized healthcare delivery.

1 October 2019 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
SKShahper KHAN
Shahper KHAN
SKShakir Khan
Shakir Khan
LMLama Misba
Lama Misba
MSMuzammil Sharief
Muzammil Sharief
AHAmiruddin Hashmi
Amiruddin Hashmi
Asad KhanAsad Khan
Asad Khan

14 April 2021 in Molecules
Verified
Journal Article
Open access
PDF file
MKMohd Wajid Ali Khan
Mohd Wajid Ali Khan
SSSubuhi Sherwani
Subuhi Sherwani
SKSaif Khan
Saif Khan
SASultan Alouffi
Sultan Alouffi
MAMD. Jahoor Alam
MD. Jahoor Alam
SKShahper KHAN
Shahper KHAN
Glioblastoma (GB) is an aggressive cancer with high microvascular proliferation, resulting in accelerated invasion and diffused infiltration into the surrounding brain tissues with very low survival rates. Treatment options are often multimodal, such as surgical resection with concurrent radiotherapy and chemotherapy. The development of resistance of tumor cells to radiation in the areas of hypoxia decreases the efficiency of such treatments. Additionally, the difficulty of ensuring drugs effectively cross the natural blood–brain barrier (BBB) substantially reduces treatment efficiency. These conditions concomitantly limit the efficacy of standard chemotherapeutic agents available for GB. Indeed, there is an urgent need of a multifunctional drug vehicle system that has potential to transport anticancer drugs efficiently to the target and can successfully cross the BBB. In this review, we summarize some nanoparticle (NP)-based therapeutics attached to GB cells with antigens and membrane receptors for site-directed drug targeting. Such multicore drug delivery systems are potentially biodegradable, site-directed, nontoxic to normal cells and offer long-lasting therapeutic effects against brain cancer. These models could have better therapeutic potential for GB as well as efficient drug delivery reaching the tumor milieu. The goal of this article is to provide key considerations and a better understanding of the development of nanotherapeutics with good targetability and better tolerability in the fight against GB.

1 January 2019 in Drug Discovery Today
Verified
Journal Article
Closed access
DADanishuddin
Danishuddin
NSNaidu Subbarao
Naidu Subbarao
MFMohammad Faheem
Mohammad Faheem
SKShahper KHAN
Shahper KHAN

2 August 2021 in Current Drug Targets
Verified
Journal Article
Closed access
PDF file
DADanishuddin
Danishuddin
NSNaidu Subbarao
Naidu Subbarao
MKMohd Khan
Mohd Khan
SASultan Alouffi
Sultan Alouffi
SKShahper KHAN
Shahper KHAN
Over the past several years, remarkable progress towards the recognition of new therapeutic targets in tumor cells has led to the discovery and development of newer scaffolds of anti-tumor drugs. The exploration and exploitation of epigenetic regulation in tumor cells are of immense importance to both the pharmaceutical and academic biomedical literatures. Epigenetic mechanisms are indispensable for the normal development and maintenance of tissue-specific gene expression. Disruption of epigenetic processes to eradicate tumor cells is among the most promising intervention for cancer control. Polycomb repressive complex 2 (PRC2), a complex that methylates lysine 27 of histone H3 to promote transcriptional silencing, is involved in orchestrating significant pathways in a cell. Overexpression of PRC2 has been found in a number of cancerous malignancies, making it a major target for anti-cancer therapy. Despite its well-understood molecular mechanism, hyperactivation and drug resistance mutations in its subunits have become a matter of discussion. This review outlines the current understanding of the components of PRC2 in active complex formation and assesses their potential as a promising therapeutic target for cancer therapy. We also review the effects of mutations in the PRC2 components, in the purview of human cancers. Finally, we discuss some of the current challenges for therapeutic drug designs targeting the PRC2 complex.

Verified
Journal Article
Open access
PDF file
MKMohd Wajid Ali Khan
Mohd Wajid Ali Khan
MAMD. Jahoor Alam
MD. Jahoor Alam
SSSubuhi Sherwani
Subuhi Sherwani
SASultan Alouffi
Sultan Alouffi
KAKhalid Al-Motair
Khalid Al-Motair
SKShahper KHAN
Shahper KHAN
Glioblastoma (GB) is an aggressive brain cancer with high microvascular proliferation. The pathological angiogenesis leads to accelerated tumour invasion and diffused infiltration into the surrounding brain tissues, with a tragically short survival rate. Various transmembrane proteins, which are embedded on the glioblastoma cancer cell surface, interact with diverse extracellular ligands/molecules present in the tumor micro-environment. These ligands play a crucial role in the development, progression, and therapeutic resistance. In the present study, we systematically screened multiple transmembrane protein receptors, and their extracellular ligands involved/implicated in GB cancer cell progression. Additionally, we analyzed the homotypic and heterotypic protein associations within glioblastoma cancer cells to better understand their role in tumor development. Ten well-known and clinically approved GB cancer drugs were selected and retrieved from online databases for molecular docking analyses with extracellular proteins. Among the different ligands analyzed, computational analysis revealed a strong interaction between fibronectin (PDB ID: 3VI4) and the majority of GB surface receptors. Furthermore, molecular docking studies between GB-approved drugs and fibronectin demonstrated the strongest binding interaction with Irinotecan, followed by Etoposide, Vincristine, etc. In conclusion, identification of ligand-drugs interactions provides valuable insights into the mechanisms underlying GB cancer cell development and potential avenues for therapeutic inhibition strategies. Our study demonstrated that Irinotecan, Etoposide, and Vincristine exhibit strong binding interactions with fibronectin, effectively disrupting its interaction with surface receptor(s). Since fibronectin receptor interactions play a crucial role in GB tumor progression, these findings suggest that targeting fibronectin could present a promising strategy to inhibit GB cell proliferation and invasion.